Background: Urea is recommended in the 2nd line treatment in moderate to severe hyponatraemia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH), when water restriction is insufficient. A posology of 0.25-0.5 g/kg daily is suggested. A usual but inadequate urea oral preparation, i. e. 10 g urea powder dissolved in 100 mL water before use, was classically compounded. Therefore the pharmacy has developed a 0.5 g/mL urea oral liquid solution in InOrpha ® with better
Introduction
Hyponatremia is defined by urea serum concentration below 135 mmol/L and become severe hyponatremia under 130 mmol/L. The etiologies of hyponatremia can be iatrogene (diuretics, antidepressors.), cardiac or adrenal insufficiency, or syndrome of inappropriate secretion of antidiuretic hormone, which is a paraneoplasic syndrome. Urea is the main nitrogen-containing substance in the human urine. It is synthesized by the liver and corresponds to the catabolism of amino-acids in excess in the organism. It represents about half of the daily osmotic load eliminated in the urine. The antinatriuretic and osmotic properties of urea can be used to normalize the serum sodium level [1] and it takes place in the European clinical practice guideline on diagnosis and treatment of hyponatraemia [2] . It is recommended in the 2nd line treatment in moderate to severe hyponatraemia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH) when water restriction is insufficient. A posology of 0.25-0.5 g/kg daily is suggested. In the literature, a classical delivery of 10 g urea powder to be dissolved in 100 mL water before use is described [2] . Urea is highly soluble in water [3] and is highly polar because of the electronegativity of its nitrogen and oxygen atoms. It will be able to engage three hydrogen bonds: two as donors and one as an acceptor. Its high melting point (132 to 135°C) suggests that the forces binding the urea molecules to each other in the solid state are relatively important (hydrogen bond type) [3] . Urea is more stable at pH between 4 and 8 and the lowest degradation is found with a buffered solution at pH 6 [4] .
The pharmacy has developed a 0.5 g/mL Urea oral liquid solution in InOrpha ® , a common commercial aromatized and suspending vehicle, with better organoleptic characteristics to improve treatment adherence and reduce the preparation time [5] . InOrpha ® was selected because this excipient has many benefits: ready to used, sugar-free and paraben free, buffered at pH 4,7, within urea stability interval. The organoleptic property allows reducing the poor palatability of urea. The microbiological stability is 3 months after opening according to manufacturer recommendations [6, 7] . However, there were no data about urea stability in the suspending vehicle, InOrpha ® [7] . A stability study was carried out according to the recommendations of the International Conference on Harmonization (ICH) to set a shelf life in order to deliver the drug to patients with quality and safety [8] . The purpose of this study was to determine physicochemical and microbiological stability of the oral liquid solution. Many analytical methods for urea in biological, environmental and food sciences were reported in the scientific literature [9] [10] [11] [12] but not for assay in hospital preparation. Even if the high-performance liquid chromatographic (HPLC) with mass spectrometry detection appears to be the most accurate method [12] , a simpler solution, developed by Koebel M., with UV-detection provides a detection limit of 0.2 mg/mL in accordance with expectations of the values from raw material tested and especially for this solution [9] . For these reasons, we decided to adapt the Koebel's method [10] and to validate it for the stability assay of urea.
Materials and methods

Formulations preparation
Urea oral liquid solution (0.5 g/mL) was prepared, according to the Good Manufacturing Practices (GMP) [13] [5] .
These preparations were packaging in amber glass bottles and stored at fridge (5°C ± 3°C) or at room temperature (24°C ± 1°C). 
Reagents
Instrumentation and chromatographic conditions
The chromatographic system included a two pumps LC -20 AD, an injector SIL -20 AC HT, a UV/VISIBLE detector SPD -M20A, a connector CBM -20 A, an oven CTO -10 AS VP (Shimadzu, Marne la Vallée, France). The stationary phase was a pre-column LiChroCart 4-4 Licrospher 100 RP-18, 5 µm (Merck Millipore, Fontenay sous Bois, France) and an anionic column, IC-Pak A HC, 4.6 × 150 mm, 10 µm (Waters ® , Milford, USA) that was kept at 30°C. The mobile phase was prepared by a mixture of acetonitrile/phosphate buffer (6:94 v/v) adjusted at pH 7 with sodium hydroxide (1N). The 5 mM phosphate buffer was prepared by a mixture of sodium dihydrogen phosphate (NaH 2 PO 4 ) and distilled water.
The injection volume of sample was 20 µL, the mobile phase flow rate set at 1 mL/min, and detection wavelength was done at 190 nm. Data collection and analysis were performed using LabSolutions ® Software (Shimadzu, Marne la Vallée, France). The HPLC equipment is available in the control laboratory of the hospital pharmacy allowing rapid analysis of the preparations extemporaneously.
Analytical validation
The analytical validation was performed according to ICH Q2R1 recommendations [14] including the assessment of system linearity, accuracy, fidelity (repeatability, intermediate precision), specificity (matrix effect, impurities, degradation products), detection and quantification limits [15] .
To study the matrix effect, 4 samples were prepared: phosphate buffer alone, a 1:10000 dilution in phosphate buffer of InOrpha To study the repeatability of the method, a fresh calibration range from 25 mg/L to 75 mg/L was prepared. Six determinations of each point range were achieved. To evaluate intermediate precision, during five day period, a new fresh calibration was prepared each day and one determination of each point range was achieved.
To validate the repeatability and the intermediate precision, the Relative Standard Deviation (RSD) has to be less than 5 %. The accuracy was assessed over 5 days from a fresh five points calibration range from 25 mg/L to 75 mg/L and three samples of known targeted concentration (30 mg/L, 50 mg/L and 60 mg/L).
To validate the accuracy, the variation coefficients and the relative errors compared to the theoretical concentrations have to be less than 5 %. A stability-indicating method is a method able to distinguish the Active Pharmaceutical Ingredient (API) from its degradation products. For the urea degradation, two samples of 0.5 g/mL urea solution in InOrpha ® diluted at 1:10000 in phosphate buffer and two samples of phosphate buffer alone were placed in the oven at 75°C during 4 days. To determine the detection and the quantification limits, the method based on the maximal amplitude of the background noise (hmax) was used. hmax was determined over a distance equal to 20 times the width at half height of the peak of the analyte assayed. Calculating the remaining percentage of the initial concentration at each time interval performed the criteria for chemical stability: urea concentration in subsequent samples greater than 90 % was considered stable. Acceptance criteria were defined as follows: -the concentration is validated analytically by QC assay (analytical quality control): ≤ 5 % for the assay series -the measured concentration does not decrease by more than 10 % with respect to the initial concentration: namely 5 % of significant and absolute loss of active ingredient in degradation observed, taking into account the fixed error of the analytical method at 5 %, the max error deviation tolerated.
In order to obtain standard solutions for HPLC analysis, a 75 mg/L stock solution was prepared. First, 0.25 g urea powder was accurately weighed in a 50 mL volumetric flask and make up to the volume with phosphate buffer. Secondly, 300 µL from the previous solution was introduced in a 20 mL volumetric flask and made up to the volume with phosphate buffer. Then, this stock solution was diluted with phosphate buffer to obtain standard solutions in the range between 25 and 75 mg/L.
Physical stability
A visual examination was performed along the stability study in order to detect a precipitation, color change, or other macroscopic manifestations. The preparation was considered physically stable if those organoleptic characteristics were not changed.
Microbiological stability
According to the European Pharmacopoeia [16] , the microbiological quality of oral preparations must achieve with success the following tests: counting of total viable aerobic germs with a maximum of 10 One bottle was stored in fridge (5°C ± 3°C) and another one was stored at room temperature (24°C ± 1°C) throughout the duration of the study. Previously, a fertility test was performed and validated to make sure no excipients present in the vehicle InOrpha ® inhibit microbial sprouting.
Results
Analytical validation Matrix effect
Chromatographic patterns from InOrpha ® diluted in phosphate buffer and Chromatograms of phosphate buffer alone were identical. Three smallest peaks not exceeding 500 uAU were observed at 1.63 min, 2.05 min and 2.51 min (Figure 1(a) and 1(b) ).
Chromatogram of urea solution diluted at 50 mg/L in phosphate buffer and chromatogram of a 1:10000 dilution in phosphate buffer of the 0.5 g/mL urea oral liquid solution in InOrpha ® gave the same peak at 2.2 min of an intensity of 65 000 uAU . As found during the tests with InOrpha ® and phosphate buffer alone, another peak not exceeding 500 uAU was observed at 2.51 min (Figure 1(c)  and 1(d) ).
Linearity
Correlation coefficients of the standard triplicate curves tested were respectively 0.9996, 0.9996 and 0.9998. Furthermore, the comparison tests of the variances, the slopes and the ordinates at the origin of the three curves do not show a significant difference to the relative risks α of 5 % (Figure 2 ).
Precision
Precision was tested for both properties: repeatability and intermediate precision (reproducibility). The maximum deviation of the RSD % was 0.33 for the repeatability and 1.78 for the intermediate precision.
Accuracy
The RSD % were estimated to 0.36, 0.31 and 0.20 respectively on the 30, 50 and 60 mg/L concentrations of the targeted control samples. The relative errors were estimated to 2.35 %, 4.69 % and 1.87 % respectively on the same serie of concentrations of quality control samples.
Specificity
After 4 days at 75°C, a decrease of urea concentration was observed from 47.5 mg/L to 37.6 mg/L which corresponds to about 21 % of loss, without the appearance of degradation peaks, undetectable at 190 nm (Figure 3 ).
Detection and quantification limits
The detection limit was determined to 0.45 mg/L (or 9.10 ng) and the quantification limit was 1.52 mg/L (or 30.34 ng).
Stability of oral liquid solution Chemical stability
Regarding to chemical stability the urea measured concentrations were within more or less 10 % than to the nominal concentration during all period tested (Table 1) .
Physical stability
Visual inspections revealed no change in color during the studied period. Macroscopic changes were observed for the samples stored at fridge (5°C +/− 3°C). Temperature between 2°C to 8°C favors precipitation and massive crystallization of urea solution (Picture 1). 
Microbiological stability
No antimicrobial properties were observed with the suspending vehicle. Urea solution prepared using GMP was found to be free of germs: no CFU were found during the study. Those results showed that the microbiological quality of the solution is not impaired during the repeated opening of the bottle over a period of 90 days, allowing the manufacture of a multidose vial.
Discussion
Regarding to the method validation, all the parameters were acceptable for a stability indicating assays. No matrix effect of the suspending vehicle InOrpha ® was observed. Phosphate buffer used as mobile phase and diluent presents three small peaks in the chromatogram that have no consequence for urea quantification because of their low intensity in comparison with urea peak . The method was considered as linear because the correlation coefficient was over 0.999 for the mean curve. Moreover, accuracy and fidelity were validated because values were inferior to 5 %. The method is stable and reliable to detect and quantify any degradation in the drug product during stability study. Indeed, the forced degradation study allowed to highlighting the degradation of the API with a loss of 21 % in urea concentration even if no degradation products could be detectable onto chromatograms. This lack of degradation products detection could be explained by the urea degradation way in aqueous solution leading to cyanate and ammonium ions, (NH 2 ) 2 CO → CNO -+ NH 4 + .
Cyanate ion further readily undergoes conversion to CO 2 and ammonia [17] . At pH 7, ammonia remains as ammonium ions, so the column will not retain it, in addition to being undetectable at 190 nm. This proposed UV-HPLC method was found to be simple, rapid, linear, accurate and stability indicating. Thus, it can be used for the assay of urea during the stability study and for routine quality control analysis in syrup, suspension preparation or for raw urea assay.
During 90 days, no significant variation of the urea concentration was observed in the solution. This concentration was always higher than 95 % of the initial concentration while the acceptance threshold was 90 %.
The pH measurements were not realized during this stability study. A previous study has shown that pH remained stable after 32 days for samples stored at fridge whereas a linear increase (r 2 = 0.99) from 5.3 to 7.2 of pH was observed for the samples stored at room temperature. At room temperature, the pH not exceeds 6.3 after fifteen days. In absence of other date, it seems better to not exceed fifteen days for stability at room temperature. Beyond fifteen days, the pH variation exceed 1 unit and can't be considered negligible [5] . Visual inspections revealed a crystallization of urea when the solution was stored at low temperature between + 2°C and + 8°C. Indeed, the 0.5 g/mL urea solution is highly concentrated and close to the saturation threshold, while urea solubility increases with temperature. Because of macroscopic changes observed, the oral liquid can't be considered stable between + 2°C and + 8°C. Therefore, storage at room temperature was proposed for better homogenization of the solution and more convenient use. Table 1 : Mean percent of urea initial concentration remaining in urea oral liquid solution after 90 days storage at room temperature (24°C +/− 1°C) (n = 6) and at fridge (5°C +/− 3°C) (n = 6). 
Conclusion
Although, all the preparations retain more than 95 % of the initial concentration after 90 days in all storage conditions, macroscopic and pH change have to be taken into account. The 0.5 g/mL urea oral liquid solution in InOrpha ® remains stable for 15 days at room temperature (24°C ± 1°C) in amber glass bottles.
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